United Therapeutics Corporation (NASDAQ:UTHR) is one of the top cheap pharmaceutical stocks to buy now. H.C. Wainwright ...

UBS analyst Ashwani Verma raised the firm’s price target on United Therapeutics (UTHR) to $415 from $385 and keeps a Buy rating on the shares. UBS ...

United Therapeutics achieves 12th consecutive quarter of growth, fueled by Tyvaso success. Discover insights on upcoming catalysts & $1B share buyback.

United Therapeutics Corporation came in with a strong topline in Q1 FY'23, growing 10% YoY. The Tyvaso label was the star, growing 40% or $66mm over the 12 months.

Looking at United Therapeutics’s peers in the therapeutics segment, some have already reported their Q4 results, giving us a hint as to what we can expect. BioMarin Pharmaceutical delivered year ...

United Therapeutics' 2018 settlement with Watson Laboratories allows Tyvaso generics to enter the market in 2026. However, opportunities for label expansion may stretch the drug's life cycle.

United Therapeutics' 2018 settlement with Watson Laboratories allows Tyvaso generics to enter the market in 2026. However, opportunities for label expansion may stretch the drug's life cycle.

United Therapeutics Corp. has terminated one of its drug candidates to help treat pulmonary arterial hypertension after it failed its most advanced drug trials. The experimental tablet called ...

United Therapeutics closed 2020 with $1.48 billion in total net revenue. The company is now studying treprostinil's inhaled form for other uses, while also expanding beyond its core PAH business ...

United Therapeutics beat analysts’ revenue expectations by 5.6% last quarter, reporting revenues of $794.4 million, up 17.2% year on year. It was a very strong quarter for the company, with a ...